Expertise in
10
conditions

Stephane De Botton

Paris, FR 
Expertise in
10
conditions
Paris, FR 
OverviewLocationsClinical Research

Overview

Stephane De Botton practices in Paris, France. Ms. De Botton is highly rated in 10 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Febrile Neutropenia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 128 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Paris, 94800, France
Other Locations
Villejuif, France
Roussy-le-village, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia
A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia
Enrollment Status: Terminated
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: MCLA-117
Study Phase: Phase 1
Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable
Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drug: Gemtuzumab ozogamicin
Study Phase: Phase 2/Phase 3
View 2 Less Clinical Trials

128 Total Publications

CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis.
CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis.
Journal: Science translational medicine
Published: September 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. De Botton's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile